| Full text | |
| Author(s): Show less - |
Moreno, Marcelo
;
Oliveira, Julia Salles
;
Brianese, Rafael Canfield
;
de Castro, Douglas Guedes
;
Sanches, Solange Moraes
;
Torrezan, Giovana Tardin
;
Santiago, Karina Miranda
;
De Brot, Marina
;
Cordeiro de Lima, Vladmir Claudio
;
Alves Makdissi, Fabiana Baroni
;
Casali Da Rocha, Jose Claudio
;
Calsavara, Vinicius Fernando
;
Carraro, Dirce Maria
Total Authors: 13
|
| Document type: | Journal article |
| Source: | CANCER MEDICINE; v. N/A, p. 13-pg., 2023-07-23. |
| Abstract | |
Background: Triple-negative breast cancer (TNBC) is the neoplasia most associated with BRCA1 germline pathogenic variants (PV) and is more likely to develop metastases than the other breast cancer (BC) subtypes, mainly in the lungs and the central nervous system (CNS). Recently, BRCA2 carriers were shown to have a higher risk for developing CNS metastases. However, the patterns of recurrence and metastases of BRCA2 carriers with TNBC are unknown.Methods: TNBC patient data attending the A.C. Camargo Cancer Center, from 1998 through 2020, were verified either by medical records or by BRCA1/2 genetic testing carried out. Multivariable logistic regression models were fit to the data to assess the independent factors for bone and CNS metastases. Adjustment was done using all independent variables with p < 0.2 in the univariable Cox model to describe the relationship between the independent variables until time of death.Results: A total of 388 TNBC patients were evaluated. We identified PV in BRCA1/2 genes in 21% (82/388), being 17.7% (69/388) in BRCA1 and only 3.3% (13/388) in BRCA2. A total of 120 patients (31%) developed distant metastases. Bone or CNS metastases were observed in 40% and 60% of BRCA2 PV carriers (p = 0.155), respectively. The BRCA2 carriers tended to have a higher likelihood of developing bone metastases (OR, 4.06; 95% CI, 0.82-20.01; p = 0.085), when compared to BRCA1 carriers (OR, 0.6; 95% CI, 0.12-2.87; p = 0.528). BRCA2 carriers had an OR of 1.75 (95% CI, 0.33-9.14; p = 0.503) for CNS metastasis development, while BRCA1 carriers had an OR of 0.72 (95% CI, 0.23-2.23; p = 0.574).Conclusions: Patients with TNBC and PV in the BRCA2 gene had higher frequencies of secondary bone involvement and CNS in the course of the disease. However, the BRCA2 PV did not represent an independent outcome predictor of metastases and overall survival. Efforts to increase the number of BRCA2 carriers among TNBC patients are crucial for determining their risk of developing bone and CNS metastases compared to BRCA2 noncarriers. (AU) | |
| FAPESP's process: | 13/23277-8 - Molecular aspects involved in the development and progression of breast ductal carcinoma: investigation of carcinoma in situ progression and the role of BRCA1 mutation in the triple negative tumor |
| Grantee: | Dirce Maria Carraro |
| Support Opportunities: | Research Projects - Thematic Grants |
| FAPESP's process: | 14/50943-1 - INCT 2014: on Oncogenomics and Therapeutic Inovations |
| Grantee: | Dirce Maria Carraro |
| Support Opportunities: | Research Projects - Thematic Grants |